Enrollment completed six months ahead of guidance in both barzolvolimab Phase 3 chronic spontaneous urticaria studies (EMBARQ-CSU 1 and 2); ...
On 4 May 2026, Guardant Health announced that the FDA approved its Guardant360 CDx liquid biopsy as a companion diagnostic for VEPPANU, enabling blood-based detection of ESR1 mutations in ...
Guardant Health, Inc. (Nasdaq: GH), a leading precision oncology company, today announced that the U.S. Food and Drug Administration (FDA) has approved the Guardant360® CDx liquid biopsy test as a ...
Enrollment completed six months ahead of guidance in both barzolvolimab Phase 3 chronic spontaneous urticaria studies (EMBARQ-CSU 1 and 2); Topline data expected in Q4 26; BLA submission planned for ...
In recent weeks, Foundation Medicine announced it expanded its collaboration with Bristol Myers Squibb to develop ...
Highl ights First quarter 2026 revenue of $200.4 million grew 2% year-over-year, reflecting stable test volume and 2% year-over-year growth ...
Companion diagnostic (CDx) tests play a critical role in personalising care by identifying optimal targeted therapies for patients based on their cancer’s unique genetic profile. The Food & Drug ...
Guardant Health, Inc. (NASDAQ: GH) shares prospered Monday. The company, a leading precision oncology concern, today ...
The Developed World Bond Fund returned -1.04% in Q1 2026, underperforming its benchmark. Read the full analysis for more ...
Discover what crypto is and how it works. A cryptocurrency is a digital form of money. They are digital assets created to be used to pay for goods and services. Cryptocurrencies can be used as a store ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results